Matthew Bin Han Ong
Matthew Bin Han Ong

Associate Editor

Matthew Ong is associate editor of The Cancer Letter. He joined the publication in 2012.

Matt’s reporting on the politics and business of cancer research and drug development has led to Congressional investigations, triggered action by FDA, CDC, FBI, and GAO, and helped change policy and standards of care.

Disclosures: Matt is an MPH, Epidemiology candidate at the Harvard T.H. Chan School of Public Health, and an NIH Research Scholar with the NIH All of Us Research Program.

His work has received more than 20 awards and is recognized by more than 15 organizations, including the National Press Club, Society of Professional Journalists, Association of Health Care Journalists, The Poynter Institute, Society of American Business Editors and Writers, National Institute for Health Care Management Foundation, American Society of Business Publication Editors, American Association of University Professors, the Washington Media Institute, and Washington, D.C. Chapter of the Society of Professional Journalists.

His stories have been picked up and cited in books, journals, and by media organizations, including The Washington Post, The Wall Street Journal, The New York Review of Books, ABC News, CBS affiliates, The Boston Globe, Science, Nature, Inside Higher Ed, The Houston Chronicle, The Philadelphia Inquirer, The Journal of the American Medical Association, The British Medical Journal, The American Journal of Managed Care, and by the President’s Cancer Panel, CEO Roundtable on Cancer, CEO Cancer Life Sciences Consortium, and the American Association for Cancer Research. He has been interviewed for documentaries, podcasts, and on public radio programs, including NPR.

Matt serves as an instructor and guest speaker for policy and advocacy organizations, at conferences, as well as at D.C.-area universities and research institutions.

He is one of five journalists selected for the 2021 class of the Health Care Performance Fellowship, the Association of Health Care Journalists's most prestigious fellowship, which is supported by The Commonwealth Fund. In 2020, he was selected from over 130 journalists by the Poynter Institute and The Washington Post to join the 2020-21 Leadership Academy for Diversity in Digital Media. He was also chosen as a fellow for AHCJ’s inaugural 2016 class of the National Cancer Reporting Fellowships at the National Cancer Institute, and the 2017 Comparative Effectiveness Research Fellowship at the Patient-Centered Outcomes Research Institute.

Matt graduated from Marquette University in 2012, majoring in journalism, psychology, as well as women’s and gender studies. His CV is available on

Latest Stories

After the stunning success of mRNA vaccines during the COVID-19 pandemic, researchers and biotech companies are racing to prove the utility of the technology in an array of non-communicable diseases—including cancer, cystic fibrosis, and sickle cell disease.
Capitol Hill
Undeterred by NIH’s failure to address a set of questions submitted seven months ago, a House oversight committee is persisting with its investigation into handling of sexual harassment complaints at institutions that receive federal funding.
White House
President Joe Biden is requesting a $920 million increase to the NIH budget in fiscal year 2024, a 1.93% boost. Of that amount, $503 million, or nearly 55%, is slated for NCI, keeping funding for the majority of other NIH institutes and centers at FY23 levels.
Academic cancer centers are facing severe staffing shortages after three years of personnel attrition during the COVID-19 pandemic—resulting in depressed levels of patient accrual to investigator-initiated and grant-funded clinical trials.
NCI Director's Report
NCI is increasing the R01 payline to the 12th percentile in fiscal year 2023, up from the 11th percentile in FY22—bringing the institute’s payline to a level not seen since 2010.
White House
President Joe Biden mentioned cancer 13 times in his impassioned State of the Union address and placed cancer research at the top of his Unity Agenda—an indication that his administration would continue to prioritize funding for cancer research in fiscal year 2024.